✦ LIBER ✦

Safety and efficacy of a biliary-excreted angiotensin converting enzyme (ACE) inhibitor, temocapril, in combination with amlodipine in advanced diabetic nephropathy

✍ Scribed by G. Yasuda; T. Kuji; K. Hasegawa; N. Hirawa; M. Kihara; Y. Toya; H. Shionoiri; S. Umemura

Publisher: Springer
Year: 2002
Tongue: English
Weight: 282 KB
Volume: 6
Category: Article
ISSN: 1342-1751
DOI: 10.1007/s101570200039

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Study on pharmacokinetics of a new bilia

Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans

✍ H. Suzuki; T. Kawaratani; H. Shioya; Y. Uji; Dr T. Saruta 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 491 KB 👁 2 views

## Abstract Despite the usefulness of angiotensin converting enzyme (ACE; EC 3.4.15.1) inhibitors for patients with renal insufficiency, some hesitation has been exercised in applying ACE inhibitors to the treatment of such patients because most ACE inhibitors are excreted mainly into the urine. In

Effects of the angiotensin II type 1 rec

Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy

✍ Atsuhisa Sato; Mitsuhisa Tabata; Koichi Hayashi; Takao Saruta 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 273 KB